Meta-analysis of Impaired Vocal Cord Mobility as a Prognostic Factor in T2 Glottic Carcinoma

McCoul, Edward D.; Har‐El, Gady

doi:10.1001/archoto.2009.47

Cited by 48 publications

(34 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The negative impact of impaired vocal cord mobility on outcome was also reported in the meta‐analysis of 35 studies, where significant differences in LC rates were seen, compared with normal mobility (OR 1.83, P < 0.001) …”

Section: Discussionsupporting

confidence: 56%

Radiotherapy for T1‐2N0 glottic cancer: a multivariate analysis of predictive factors for the long‐term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients

Al‐Mamgani

Rooij

Woutersen

et al. 2013

Clinical Otolaryngology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 56%

Radiotherapy for T1‐2N0 glottic cancer: a multivariate analysis of predictive factors for the long‐term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients

Al‐Mamgani

Rooij

Woutersen

et al. 2013

Clinical Otolaryngology

View full text Add to dashboard Cite

show abstract

“…The possible prognostic importance of impaired cord mobility in T2 glottic cancer[19] was evaluated by McCoul and Har-El[20] who pooled data from 21 reports and found a statistically better outcome in T2a disease. Our data confirm a prognostic difference based on substage, including a trend for better local control in T2a vs T2b disease, and significant differences in locoregional control, disease-free survival, and overall survival, but no differential effect by fractionation.…”

Section: Discussionmentioning

confidence: 99%

Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord (RTOG 9512)

Trotti

Zhang

Bentzen

et al. 2014

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose To compare hyperfractionation versus standard fractionation for T2N0 vocal cord carcinoma in a randomized controlled trial. Methods and Materials Patients with T2 vocal cord cancer were stratified by substage (T2a vs. T2b) and randomly assigned to receive either hyperfractionation (HFX) to 79.2 Gy in 66 fractions of 1.2 Gy given twice a day, or standard fractionation (SFX) to 70 Gy in 35 fractions given once a day. The trial was designed to detect a 55% reduction in the local failure hazard rate with 80% statistical power. Results Between April 1996 and July 2003, 250 patients were enrolled. Of 239 patients analyzable for outcomes, 94% were male, 83% had KPS 90-100, and 62% had T2a tumor. Median follow-up for all surviving patients was 7.9 years (range: 0.6 – 13.1). The 5-year local control (LC) rate was 8 points higher (but not statistically significant: p=0.14) for HFX (78%) vs SFX (70%), corresponding to a 30% hazard rate reduction. Five-year disease-free survival (DFS) was 49% vs 40% (p=0.13) and overall survival (OS) 72% vs 63% (p=0.29). HFX had higher rates of acute skin, mucosal, and laryngeal toxicity. Grade 3-4 late effects were similar with 5-year cumulative incidence of 8.5% (3.4-13.6%) after SFX and 8.5% (3.4-13.5%) after HFX. Conclusions Five-year local control was modestly higher with HFX compared to SFX for T2 glottic carcinoma, but the difference was not statistically significant. These results are consistent with prior studies of hyperfractionation showing a benefit in local control. Substaging by T2a vs T2b carries prognostic value for DFS and OS. For cost and convenience reasons other altered fractionation schedules have been adopted in routine practice.

show abstract

“…Our data is consistent with other published results that reported no prognostic significance on LC [23,24] . However, other studies, including a meta-analysis did suggest its adverse impact on LC [7,25,26]. …”

Section: Discussionmentioning

confidence: 99%

Definitive radiotherapy for early stage glottic cancer by 6 MV photons

Tong

Ngan

et al. 2012

Head Neck Oncol

View full text Add to dashboard Cite

PurposeTo evaluate the clinical outcome of early glottic cancer (GC) treated by primary radiotherapy (RT) with 6 MV photons.Methods and materialsWe retrospectively reviewed the medical records of 695 consecutive patients with T1N0 and T2N0 GC treated between 1983 and 2005 by RT in our institution. Clinical outcome in terms of local control (LC), overall survival (OS) and cause- specific survival (CSS) rate were evaluated.ResultsThe median follow-up time was 10.5 years. The 10-year actuarial LC rates were as follows: T1A, 91%; T1B, 87%; T2, 77%. The 10-year OS were as follows: T1, 74.2%; T2, 70.7%. The 10-year CSS were as follows: T1, 97.7%; T2, 97.1%.Poorly differentiated histology and tumor biologically effective dose < 65 Gy15 were adverse factors in both LC of T1 and T2 disease. Involvement of anterior commissure was an adverse factor in both LC and CSS of T1 disease. Subglottic extension was associated with poor LC in T2 disease whereas hemoglobin <13.0 was associated with poor LC and CSS of T2 disease.ConclusionPrimary RT remains an option among the various standard treatments for early GC. Clinical treatment outcome by 6MV photons is similar and comparable to historic data of Cobalt-60 and 2 MV photons.

show abstract

Meta-analysis of Impaired Vocal Cord Mobility as a Prognostic Factor in T2 Glottic Carcinoma

Cited by 48 publications

References 57 publications

Radiotherapy for T1‐2N0 glottic cancer: a multivariate analysis of predictive factors for the long‐term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients

Radiotherapy for T1‐2N0 glottic cancer: a multivariate analysis of predictive factors for the long‐term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients

Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord (RTOG 9512)

Definitive radiotherapy for early stage glottic cancer by 6 MV photons

Contact Info

Product

Resources

About